Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1##

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which Z is a heterocyclic group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R.sub.1 ; or a group ##STR3## in which A.sub.1, A.sub.2 and A.sub.3 complete a 5-membered aromatic ring and A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.2 and the other is nitrogen or CR.sub.3, or A.sub.2 is oxygen or sulphur, one of A.sub.1 and A.sub.3 is CR.sub.2 and the other is CR.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen, halogen, CN, OR.sub.4, SR.sub.4, N(R.sub.4).sub.2, NHCOR.sub.4, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sub.4, NHNH.sub.2, NO.sub.2, COR.sub.4, COR.sub.

Abstract: A skin-care composition comprising a topically acceptable oil-in-water or water-in-oil emulsion base and from 1,000 to 15,000 I Ug.sup.-1 of a C.sub.1-10 alkyl ether or a C.sub.3-10 alkyl ester of retinol is disclosed. The composition preferably contains an anti-oxidant such as butylated hydroxytoluene or butylated hydroxyanisole. The composition is useful in promoting epidermal mitosis.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein X is CO and Y is NH or O, or X is NH and Y is CO;Z is CH.sub.2, O, S or NR.sub.3 wherein R.sub.3 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 alkenyl-methyl, phenyl or phenyl C.sub.1-4 alkyl either of which phenyl moieties may be substituted by one or two of halogen, CF.sub.3, C.sub.1-6 alkoxy or C.sub.1-6 alkyl; and R.sub.a is not present; orZ is CH or N and R.sub.a is as defined for R.sub.3 above;R.sub.b is present when X--Y--R.sub.2 is attached at the phenyl ring and is selected from hydrogen, halogen, CF.sub.3, hydroxy, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;R.sub.1 is hydrogen, halogen, CF.sub.3, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonylamino, N-(C.sub.1-6 alkylsulphonyl)-N-C.sub.1-4 alkylamino, C.sub.1-6 alkylsulphinyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C.sub.

Abstract: An oral hygiene composition contains (a) from 0.01 to 2% by weight of Triclosan, (b) from 2 to 10% by weight of polyethylene glycol of molecular weight from 200 to 1000, and (c) 0.1 to 2% by weight of oil-based flavor material.The polyethylene glycol helps to maintain an effective level of orally available Triclosan.

Abstract: A method for the treatment and/or prophylaxis of disorders associated with pulmonary hypertension and/or disorders associated with right heart failure, in mammals, which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic, non-toxic, amount of a compound of formula (I): ##STR1## wherein A.sup.1 represents CR.sub.1, N or N.sup.+ --O.sup.- ; when A.sup.1 represents N or N.sup.+ --O.sup.-, R.sup.2 represents hydrogen;when A.sup.1 represents CR.sub.1 then:either;one of R.sub.1 and R.sub.2 is hydrogen and the other is a group R.sup.a wherein R.sup.a is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.

Abstract: A pharmaceutical product comprising a potassium channel activator antihypertensive agent and a .beta.-blocker antihypertensive agent as a combined preparation for simultaneous, separate or sequential use in therapy of hypertension.

Abstract: .beta.-Lactam antibiotics have the formula (Ia) or are pharmaceutically acceptable salts or pharmaceutically acceptable in vivo hydrolysable esters thereof: ##STR1## in which the group CO.sub.2 R.sup.1 is carboxy or a carboxylate anion. The use of the compounds and processes for their preparation are disclosed.

Abstract: An anti-caries composition has a source of hydrogen citrate ions, preferably an alkali metal hydrogen citrate salt, an oxalate salt and an orally acceptable excipient, and optionally further comprises an ionic fluorine-containing compound. The composition may be in the form of dentifrice when silica is the preferred abrasive, or a mouthwash.

Abstract: A compound of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 and R.sup.2 may each represent hydrogen or alkyl providing that at least one of R.sup.1 or R.sup.2 represents alkyl;R.sup.3 and R.sup.4 each represent hydrogen or R.sup.3 and R.sup.4 together represent a bond;n represents an integer 1 or 2;and m represents an integer 1 or 2; a composition containing such a compound and the use of such compounds and compositions in medicine.

Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## which process comprises reacting a compound of formula (II): ##STR2## wherein the amino group is optionally protected, Y is iodo, optionally substituted benzylthio or (phenacylmethyl)thio, with a compound of formula (III): ##STR3## wherein Q is a leaving group, R.sub.x and R.sub.y are protected hydroxymethyl or acyloxymethyl, or group(s) convertible to hydroxymethyl or acyloxymethyl; and R.sub.z is hydrogen or a group convertible thereto; and thereafter converting Y to X is hydroxy by means of hydrolysis, or to X is hydrogen by means of reduction; converting R.sub.x and R.sub.y when other than hydroxymethyl or acyloxymethyl, to hydroxymethyl or acyloxymethyl, optionally converting R.sub.x /R.sub.y hydroxymethyl to acyloxymethyl or vice versa, deprotecting the 2-amino group where necessary and converting R.sub.

Abstract: An oral hygiene composition comprising a silica base, from 1 to 10% by weight of the composition of a water solouble non-toxic strontium salt, a fluoride source providing from 250 ppm to 2000 ppm of fluoride in the composition, and a dentally acceptable carrier, provided that when the strontium salt is other than strontium acetate the silica base has a BET surface area of from 50 to 400 m.sup.2 /g.The composition has improved anti-sensitivity properties coupled with high levels of available fluorine.

Abstract: A veterinary composition comprising 75-85% of an actively absorbed monosaccharide, from 3.5 to less than 5% of an actively absorbed naturally occurring amino acid, 5-10% of one or more citrate salts. The composition is useful in the treatment of diarrhoea in domestic animals such as calves.

Abstract: Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond;A.sup.2 represents a benzene ring having in total up to five substituents; andn represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

Abstract: A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.

Abstract: A hair care composition comprising at least 1,000 IUg.sup.-1 of an ester of retinol in a topically acceptable carrier is useful for increasing the diameter of growing hair.

Abstract: Novel compounds of formula (I), processes for their preparation, and their use as pharmaceutical agents are described: ##STR1## in which X represents a group ##STR2## wherein one of Y and Z represents nitrogen and the other represents CR where R is selected from halogen, CN, OR.sup.1, SR.sup.1, N(R.sup.1).sub.2, NHR.sup.1, NHCOR.sup.1, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sup.1, NHNH.sub.2, COR.sup.1, COR.sup.2, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl or C.sub.1-2 alkyl substituted with OR.sup.1, N(R.sup.1).sub.2, SR.sup.1, CO.sub.2 R.sup.1, CON(R.sup.1).sub.2 or one or two halogen atoms, in which R.sup.1 is hydrogen or C.sub.1-2 alkyl and R.sup.2 is OR.sup.1, NH.sub.2 or NHR.sup.1 ; and each of p and q independently represents an integer of 2 to 4.

Abstract: A method for the treatment and/or prophylaxis of hyperglycemia in mammals including administration to the mammal of an effective, nontoxic amount of either a compound of formula (I), ##STR1## or a pharmaceutically acceptable acid addition salt thereof; or of a compound of formula (II), ##STR2## or a pharmaceutically acceptable acid addition salt thereof.